Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with < em > Staphylococcus Aureus < /em > by pharmacokinetic/pharmacodynamic analysis
J Chemother. 2024 Apr 22:1-8. doi: 10.1080/1120009X.2024.2343963. Online ahead of print.ABSTRACTOmadacycline is an FDA-approved agent for community-acquired bacterial pneumonia (CABP). The purpose of this study is to evaluate the effectiveness of omadacycline for treating CABP patients infected with Staphylococcus aureus, including Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Susceptible Staphylococcus aureus (MSSA), using pharmacokinetic/pharmacodynamic (PK/PD) analysis. Monte Carlo simulations (MCSs) were performed by utilizing omadacycline pharmacokinetic (PK) parameters, minimum inhibitory concent...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Gaoqi Xu Xin Liu Jiaqi Wang Yuqing Mei Dihong Yang Chaoneng He Like Zhong Junfeng Zhu Haiying Ding Luo Fang Source Type: research
Long-term remission after upfront autologous hematopoietic stem cell transplant for CD5 < sup > + < /sup > diffuse large-B cell lymphoma
J Chemother. 2024 Apr 23:1-9. doi: 10.1080/1120009X.2024.2340147. Online ahead of print.ABSTRACTCD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype characterized by an inferior outcome. While dose-dense therapy shows promising activity, the optimal management remains to be determined. To evaluate the benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT), we retrospectively reviewed the medical records of 47 consecutive patients with newly diagnosed de novo CD5+ DLBCL. Of 19 patients ≤ 70 of age with age-adjusted International Prognostic Index 2-3, eight underwent upfront ASCT, and ni...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Yosuke Masamoto Akira Honda Aya Shinozaki-Ushiku Tetsuo Ushiku Mineo Kurokawa Source Type: research
Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with < em > Staphylococcus Aureus < /em > by pharmacokinetic/pharmacodynamic analysis
J Chemother. 2024 Apr 22:1-8. doi: 10.1080/1120009X.2024.2343963. Online ahead of print.ABSTRACTOmadacycline is an FDA-approved agent for community-acquired bacterial pneumonia (CABP). The purpose of this study is to evaluate the effectiveness of omadacycline for treating CABP patients infected with Staphylococcus aureus, including Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Susceptible Staphylococcus aureus (MSSA), using pharmacokinetic/pharmacodynamic (PK/PD) analysis. Monte Carlo simulations (MCSs) were performed by utilizing omadacycline pharmacokinetic (PK) parameters, minimum inhibitory concent...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Gaoqi Xu Xin Liu Jiaqi Wang Yuqing Mei Dihong Yang Chaoneng He Like Zhong Junfeng Zhu Haiying Ding Luo Fang Source Type: research
Long-term remission after upfront autologous hematopoietic stem cell transplant for CD5 < sup > + < /sup > diffuse large-B cell lymphoma
J Chemother. 2024 Apr 23:1-9. doi: 10.1080/1120009X.2024.2340147. Online ahead of print.ABSTRACTCD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype characterized by an inferior outcome. While dose-dense therapy shows promising activity, the optimal management remains to be determined. To evaluate the benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT), we retrospectively reviewed the medical records of 47 consecutive patients with newly diagnosed de novo CD5+ DLBCL. Of 19 patients ≤ 70 of age with age-adjusted International Prognostic Index 2-3, eight underwent upfront ASCT, and ni...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Yosuke Masamoto Akira Honda Aya Shinozaki-Ushiku Tetsuo Ushiku Mineo Kurokawa Source Type: research
Efficacy and safety of generic cefoperazone/sulbactam versus branded cefoperazone/sulbactam in the treatment of bacterial infections: a systematic review and meta-analysis
This study aim to assess the clinical efficacy and safety of generic cefoperazone/sulbactam compared to the branded cefoperazone/sulbactam (Sulperazon) in treating bacterial infections through a meta-analysis. Searches were conducted across PubMed, Embase, Cochrane Library, CNKI, WanFang, VIP databases, and Clinical Trials database, resulting in the inclusion of 11 studies comprising 7 randomized controlled trials (RCTs) and 4 retrospective cohort studies (RCSs). Meta-analysis of the RCTs indicated no statistical differences in clinical success rates, clinical cure rates, microbiological eradication rates, and incidence of...
Source: Journal of Chemotherapy - April 22, 2024 Category: Cancer & Oncology Authors: Rui Wu Xuechang Wang Pumei Cui Wei Chen Wanqi Yang Yong Lai Source Type: research
Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale
J Chemother. 2024 Apr 17:1-13. doi: 10.1080/1120009X.2024.2340885. Online ahead of print.ABSTRACTA time-course questionnaire survey using the chemotherapy-induced taste alteration scale (CiTAS) was conducted in patients with advanced urothelial carcinoma (UC) treated with systemic chemotherapy and/or immunotherapy. A total of 37 patients receiving systemic therapy with enfortumab vedotin (EV), platinum-based chemotherapy and immune checkpoint inhibitors were included in this study. No significant changes were observed in any of the CiTAS subscales during platinum-based chemotherapy and immune checkpoint inhibitor treatment...
Source: Journal of Chemotherapy - April 17, 2024 Category: Cancer & Oncology Authors: Makito Miyake Nobutaka Nishimura Yuki Oda Tatsuki Miyamoto Mitsuru Tomizawa Takuto Shimizu Shunta Hori Yosuke Morizawa Daisuke Gotoh Yasushi Nakai Kazumasa Torimoto Tomomi Fujii Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Correction
J Chemother. 2024 May;36(3):264-265. doi: 10.1080/1120009X.2023.2276538. Epub 2023 Nov 20.NO ABSTRACTPMID:38616651 | DOI:10.1080/1120009X.2023.2276538 (Source: Journal of Chemotherapy)
Source: Journal of Chemotherapy - April 15, 2024 Category: Cancer & Oncology Source Type: research
Daptomycin and ceftaroline combination for the treatment of persistent methicillin-resistant < em > Staphylococcus aureus < /em > bloodstream infections: a case series and literature review
In this report, we present a case series of 7 patients who failed vancomycin and then were treated with daptomycin and ceftaroline for persistent MRSA BSIs. The median age (IQR) of the included patients was 59 (48-67), with 5 male and 2 female patients. Six patients (85.7%) had a clinical cure for their persistent BSIs. The median time (IQR) for sterilization of MRSA BSIs after initiation of daptomycin and ceftaroline combination was 2 days (1-3). Among the patients who had clinical cures, the median time for clinical cures (IQR) was 6 weeks (4.5-6 weeks). The combination of daptomycin and ceftaroline could be an excellent...
Source: Journal of Chemotherapy - April 12, 2024 Category: Cancer & Oncology Authors: Yazed S Alsowaida Ahmed Alsolami Thamer A Almangour Source Type: research
Evaluating omadacycline dosing regimens against drug-resistant pathogens including < em > Staphylococcus aureus < /em > , < em > Streptococcus pneumoniae < /em > and < em > Haemophilus influenzae < /em > in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation
In conclusion, approved oral/intravenous loading and maintenance doses of omadacycline showed enough efficacy in the treatment of ABSSI and CABP caused by the main drug-resistant pathogens.PMID:38591989 | DOI:10.1080/1120009X.2024.2339706 (Source: Journal of Chemotherapy)
Source: Journal of Chemotherapy - April 9, 2024 Category: Cancer & Oncology Authors: Xiao-Chen Wei Ming-Feng Zhao Xia Xiao Source Type: research
